If you are perimenopausal or postmenopausal and you have noticed that losing weight feels harder than it ever did before, you are not imagining it. The biology of menopause genuinely changes how your body manages fat, blood sugar, and hunger. GLP-1 medications, including semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound), are now being used by millions of women in midlife. Here is what the science actually says about them, and what you need to know before making any decisions.

What GLP-1 Medications Are

Semaglutide and tirzepatide are FDA-approved prescription medications, not supplements or wellness products. Semaglutide was originally developed for type 2 diabetes management and is FDA-approved for chronic weight management under the brand name Wegovy. Tirzepatide follows a similar path, approved for both type 2 diabetes (Mounjaro) and weight management (Zepbound).

These medications work by mimicking hormones your body naturally produces after eating. GLP-1, or glucagon-like peptide-1, is released in response to food and sends signals to the brain that reduce appetite and promote a sense of fullness. GLP-1 medications also slow gastric emptying, meaning food moves through the stomach more slowly, which keeps blood sugar more stable and extends the feeling of satiety. Tirzepatide goes a step further by also mimicking GIP (glucose-dependent insulinotropic polypeptide), another gut hormone that improves insulin sensitivity. Both classes of medication improve how the body handles blood sugar, which becomes particularly important during and after menopause.

Why Menopause Makes Weight Management Harder

The weight changes many women experience during perimenopause are not simply a matter of slowing down or eating more. Declining estrogen directly affects metabolism in several ways. It increases insulin resistance, which means the body needs more insulin to process glucose and is more likely to store excess energy as fat. It accelerates the loss of lean muscle mass, and muscle burns more calories at rest than fat does. Estrogen decline also shifts where fat is deposited, favoring the abdomen rather than the hips and thighs, resulting in increased visceral fat. Visceral fat is metabolically active and associated with higher risks of cardiovascular disease and type 2 diabetes.

On top of this, the hormones that regulate hunger, including leptin and ghrelin, are disrupted during menopause. Many women report feeling hungrier or less satisfied after eating than they used to, even when their diet has not changed. This is not a failure of willpower. It is the result of hormonal changes that affect the brain’s appetite regulation centers. GLP-1 medications target some of these same pathways, which is part of why researchers are looking at them specifically in the context of menopause.

What the Research Shows for Menopausal Women

The clinical trial data on GLP-1 medications is substantial. The STEP-1 trial found that semaglutide produced an average weight loss of 14.9% over 68 weeks in adults with obesity or overweight. The SURMOUNT-1 trial found that tirzepatide produced an average weight loss of 20.2% over 72 weeks, making it one of the most effective non-surgical weight loss interventions studied to date.

More specific to this population, a 2024 study published in the journal Menopause examined postmenopausal women receiving semaglutide alongside hormone therapy, and compared them to women on semaglutide alone. The women on combined treatment lost significantly more weight at every checkpoint measured: 3, 6, 9, and 12 months. This adds to a growing body of evidence suggesting that for postmenopausal women, hormone therapy and GLP-1 medications may have complementary effects, with hormone therapy addressing the estrogen-driven changes that increase insulin resistance and fat redistribution, while GLP-1 medications directly target appetite and glucose regulation.

This research is still developing, and it is important not to overstate conclusions from individual studies. But the signals are meaningful enough that clinicians are paying close attention.

FDA-Approved Medications Versus Compounded Products

As demand for GLP-1 medications has grown, so has the availability of compounded versions sold online, often at lower prices and without a prescription. It is important to understand the difference.

FDA-approved semaglutide and tirzepatide have undergone rigorous clinical testing for safety, efficacy, purity, and dosing accuracy. Compounded versions have not. In 2026, the FDA issued warnings about fraudulent compounded semaglutide and tirzepatide products, citing risks including contamination, mislabeling of ingredients or doses, and the use of salt forms of the active ingredient that have not been tested for safety in humans.

Buying GLP-1 compounds online without medical supervision is not a shortcut to the same outcome. It carries real risks that the regulated versions do not. If cost or access is a barrier, that is a conversation worth having with a doctor or pharmacist, not a reason to turn to unregulated products.

Who These Medications May Be Appropriate For

GLP-1 medications are not appropriate for everyone, and they are not intended as a cosmetic weight loss tool for women who are already at a healthy weight. In clinical guidelines, they are indicated for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as type 2 diabetes, insulin resistance, hypertension, or metabolic syndrome.

For perimenopausal and postmenopausal women who meet these criteria, GLP-1 medications may offer meaningful benefits beyond weight loss, including improved insulin sensitivity, reduced cardiovascular risk markers, and better blood sugar regulation. They also have side effects that need to be considered, including nausea, gastrointestinal discomfort, and, with longer-term use, questions about muscle mass preservation that are particularly relevant for women at higher risk of osteoporosis.

How to Have the Conversation with Your Doctor

If you are considering asking about GLP-1 medications, preparation makes the conversation more productive. Bring information about your current weight, any related health conditions, your menopause symptoms and stage, and any medications or hormone therapy you are already taking. Ask specifically whether you meet the criteria for a GLP-1 medication, which one might be most appropriate for your situation, and whether it would be considered alongside or instead of hormone therapy.

It helps to ask about side effects, monitoring expectations, and what success looks like over time. These are not one-size-fits-all medications, and the right answer depends on your individual health picture.

A Realistic View of an Evolving Area

The research on GLP-1 medications in the context of menopause is genuinely promising, but it is also still accumulating. What is clear is that the hormonal changes of menopause create specific metabolic challenges, and that for some women, these medications may be a meaningful part of a broader plan that includes nutrition, physical activity, and hormone therapy where appropriate.

What is equally clear is that these are serious prescription medications with real effects and real risks. Self-prescribing or purchasing unregulated versions is not a safe alternative to working with a qualified healthcare provider. If this is something you are considering, start that conversation with your doctor. You deserve accurate information and proper medical assessment, not a shortcut.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment.